IP Library Granted Patent US 6,891,027
Granted Patent B2
US 6,891,027 · App. 09/850,715 · Granted May 10, 2005

Modulating the immune response

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,891,027
App. No.
09/850,715
Granted
May 10, 2005
Kind
B2
Abstract

Coupling of C3d molecules or ligands of CD21 or CD19 to an antigen alters the level of immune response to the immunogen upon its administration to an individual. For C3d, the magnitude of the effect is dependent on the number of C3d molecules included in the conjugate. Conveniently, C3d molecules or CD21/CD19 ligands are coupled to an immunogen in fusion polypeptides which may be produced by expression from coding nucleic acid, for instance by culturing host cells containing the nucleic acid. Other means of associating the molecules include chemical cross-linking and co-expression on the surface of a carrier structure. Administration of compositions comprising, in a preferred embodiment, C3d molecules and an immunogen of interest may be used prophylactically (by virtue of the immunological memory induced) or therapeutically. The administration may be for the purpose of raising antibodies to the immunogen. A T-cell response may also be induced.

Claims (6)

1. A nucleic acid encoding a fusion protein comprising a peptide or polypeptide antigen and more than one murine or human C3d molecule.

2. A host cell comprising the nucleic acid according to claim 1 .

3. A composition comprising the nucleic acid according to claim 1 and a pharmaceutically acceptable excipient or carrier.

4. An expression vector comprising the nucleic acid according to claim 1 and further comprising regulatory sequences for expression of the fusion protein.

5. A host cell comprising the vector according to claim 4 .

6. A composition comprising the vector according to claim 4 and a pharmaceutically acceptable excipient or carrier.

Assignments (1)
CHANGE OF NAME Recorded Nov 8, 2007
From: CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD
To: CAMBRIDGE ENTERPRISE LTD
Reel/Frame 020109/0089 →